Buy (Page 6)

phototechno Amylyx Pharmaceuticals (NASDAQ:AMLX) has signed an agreement with Eiger BioPharmaceuticals (OTC:EIGRQ) to acquire the rights to the latter’s Phase 3-ready GLP-1 receptor antagonist, Avexitide. Cambridge, Massachusetts-based Amylyx (AMLX) has agreed to pay $35.1M plus other payments for the acquisition, the company announced in an SEC filing late Friday. TheContinue Reading